| Ytd | 35.07% | |
| 1y | -13.77% |
| Open | 12.28 | Prev Close | 12.02 | Low | 11.90 | High | 12.30 | Mkt Cap | 6.20M |
| Vol | 318.26K | Avg Vol | 513.09K | EPS | 0.08 | P/E | 152.63 | Forward P/E | N/A |
| Beta | -2.86 | Short Ratio | 0.43 | Inst. Own | 0.08% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 11.52 | 200-d Avg | 16.61 | 1yr Est | 0.00 |
NCI News
[url="]Exelixis, Inc.[/url] (Nasdaq: EXEL) today announced results from a subgroup analysis of the p
Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer PR Newswire
NTG Clarity Networks Inc. (NCI:CA) Q1 2026 Earnings Call Transcript
ImmunityBio, Inc. ([url="]NASDAQ: IBRX[/url]), a commercial-stage immunotherapy company, today annou
HONG KONG, May 15, 2026 (GLOBE NEWSWIRE) -- On May 8, 2026, Neo-Concept International Group Holdings
NTG Clarity Networks Inc. (NCI:CA) Q4 2025 Earnings Call Transcript
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an inve
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an inve
Amazon may acquire Globalstar Inc., shares soared in pre-market trading. Other gainers include Turbo
Reliance Industries is set to fund a $300B Texas refinery, a move that could boost India ETFs holdin
NEW YORK CITY, NEW YORK / ACCESS Newswire / February 24, 2026 / On February 11, 2026, Neo-Concept In
Hong Kong, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Neo-Concept International Group Holdings Limited (Nasda
Hong Kong, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Neo-Concept International Group Holdings Limited (Nasda
Hong Kong, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Neo-Concept International Group Holdings Limited (“NCI”
NTG Clarity Networks Inc. ( NCI:CA ) Q3 2025 Earnings Call November 13, 2025 9:00 AM EST Company Par
SOUTH SAN FRANCISCO, Calif., Oct. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc.
WALTHAM, Mass. and BOULDER, Colo., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasd
Data demonstrate potent suppression of MAPK signaling and viability in KRAS mutant cell lines, as we
ROCKVILLE, Md., Oct. 22, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (I-Mab or the Company), is a
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (
PHILADELPHIA and VANCOUVER, British Columbia, Aug. 25, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutic